II. Indications
- Resistant Dermatophyte Infections (e.g. Tinea Pedis, Tinea Cruris, Tinea Corporis)
- FDA approved in adults and children over age 12 years old
- As an exception, FDA approved for Tinea Cruris down to age >2 years
III. Mechanism
- Topical synthetic allylamine (similar to Terbinafine)
- Broad-spectrum Antifungal activity
- Blocks Ergosterol synthesis (key component in the fungal cell wall)
- Inhibits squalene epoxidase, the enzyme that converts squalene to ergosterol
IV. Medications: Topical
- Naftifine HCl (Naftin)
- Cream: 1%, 2%
- Gel: 1%, 2%
V. Dosing
- Apply cream once daily (or gel twice daily) for up to 4 weeks
VI. Safety
- Pregnancy Category B
- Unknown safety in Lactation
VII. Efficacy
- Effective in refractory cases of superficial Tinea Infections
- Less effective in Cutaneous Candidiasis
VIII. Resources
- Naftifine Gel (DailyMed)
- Naftifine Cream (DailyMed)